Repository logo
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
    Communities & Collections
    Research Outputs
    Fundings & Projects
    People
    Organizations
    Statistics
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. Chung Shan Medical University
  3. Pure學術人才庫轉入
  4. SGLT-2 Inhibitors and the Risk of Chronic Obstructive Pulmonary Disease Exacerbations and Mortality in Chronic Obstructive Pulmonary Disease Patients
 
  • Details
Options

SGLT-2 Inhibitors and the Risk of Chronic Obstructive Pulmonary Disease Exacerbations and Mortality in Chronic Obstructive Pulmonary Disease Patients

Journal
Annals of the American Thoracic Society
Date Issued
2025-06-01
Author(s)
JAMES CHENG-CHUNG WEI  
DOI
10.1513/AnnalsATS.202407-703OC
URI
https://www.scopus.com/pages/publications/105007481907
https://scholars.csmu.edu.tw/handle/123456789/25300
Abstract
Rationale: Patients with chronic obstructive pulmonary disease (COPD) are susceptible to acute exacerbations, cardiovascular disease, and premature death. Objectives: To compare the risk of COPD exacerbation, cardiovascular diseases, and mortality between SGLT-2 (sodium-glucose cotransporter-2) inhibitor use and nonuse in patients with type 2 diabetes mellitus (T2DM) and COPD. Methods: The study included 299,168 patients with diagnoses of T2DM and COPD in the National Health Insurance Research Database from January 1, 2009, to December 31, 2020. Cox proportional hazards models were used to examine the relative hazard of the primary outcome (a composite of hospitalization for COPD, noninvasive positive-pressure ventilation [NIPPV], invasive mechanical ventilation, and all-cause mortality) and secondary outcomes: major adverse cardiovascular events, hospitalization for COPD, NIPPV, invasive mechanical ventilation, lung cancer, and mortality between SGLT-2 inhibitor users and nonusers. We used propensity score matching to select 1,288 pairs of SGLT-2 inhibitor users and nonusers. Results: In the matched cohorts, SGLT-2 inhibitor use was associated with a significantly lower risk of the primary outcome (multivariable-adjusted hazard ratio [aHR], 0.79 [95% confidence interval (CI), 0.67–0.93]), NIPPV (aHR, 0.48 [95% CI, 0.27–0.87]), hospitalization for COPD (aHR, 0.82 [95% CI, 0.69–0.98]), and mortality (aHR, 0.64 [95% CI, 0.43–0.95]), than SGLT-2 inhibitor nonuse. Subgroup and dose–response analyses showed that SGLT-2 inhibitor use was associated with a significantly lower risk of mortality, NIPPV, and hospitalization for COPD (P, 0.05) than nonuse of SGLT-2 inhibitors. Conclusions: This population-based cohort study showed that SGLT-2 inhibitor use was associated with a lower risk of the primary outcome, COPD exacerbations, ventilator support, and mortality than SGLT-2 inhibitor nonuse in patients with T2DM and COPD. SGLT-2 inhibitors may have a role in treating patients with COPD and diabetes.
Type
journal article
Make it your own

DSpace-CRIS can be extensively configured to meet your needs. Decide which information need to be collected and available with fine-grained security. Start updating the theme to match your Institution's web identity.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback